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To identify proteins undergoing glutathionylation (formation of
protein-glutathione mixed disulfides) in human T cell blasts, we
radiolabeled the glutathione pool with 35S, exposed cells to the
oxidant diamide, and analyzed cellular proteins by two-dimen-
sional electrophoresis. One of the proteins undergoing glutathio-
nylation was identified by molecular weight, isoelectric point, and
immunoblotting as thioredoxin (Trx). Incubation of recombinant
human Trx with glutathione disulfide or S-nitrosoglutathione led
to the formation of glutathionylated Trx, identified by matrix-
assisted laser desorption ionization–time-of-flight mass spectrom-
etry. The glutathionylation site was identified as Cys-72. Gluta-
thionylation of rhTrx abolished its enzymatic activity as insulin
disulfide reductase in the presence of NADPH and Trx reductase.
Activity was, however, regained with sigmoidal kinetics, indicating
a process of autoactivation due to the ability of Trx to de-
glutathionylate itself. These data suggest that the intracellular
glutathioneglutathione disulfide ratio, an indicator of the redox
state of the cell, can regulate Trx functions reversibly through
thiol-disulfide exchange reactions.
Thioredoxin (Trx; ref. 1), a ubiquitous redox protein, is anessential cofactor electron donor for ribonucleotide reduc-
tase, but also has many other cellular functions, including
regulation of transcription factors, apoptosis, and antioxidant
activity and can act exogenously as a redox active growth factor
(1, 2). The catalytic activity of Trx resides in its active site where
the two redox active Cyss (Cys-31 and Cys-34 in human Trx)
undergo reversible oxidationreduction. In addition to the con-
served Cys residues in the active site, three additional structural
Cys residues (Cys-61, Cys-68, and Cys-72) are present in the
structure of human Trx.
The present paper describes the experiments that led us to the
conclusion that Trx can undergo glutathionylation in T cells
exposed to oxidative stress. Protein glutathionylation, the for-
mation of a disulfide between a Cys in a protein and the Cys in
the tripeptide glutathione (GSH), is a modification that can be
induced in cells by oxidative stress. Glutathionylation can occur
by direct oxidation of a protein and GSH, by a thiol-disulfide
exchange between a protein Cys and oxidized glutathione
(GSSG), and also with the intermediacy of S-nitrosoglutathione
(GSNO; refs. 3 and 4). Glutathionylation of proteins is revers-
ible, as those proteins can be reduced by glutaredoxins (5, 6), and
the process serves to regulate protein functions by the redox state
of the cell (i.e., by the GSSGGSH ratio; refs. 7–9).
To demonstrate the glutathionylation of Trx, we first labeled
the intracellular GSH pool of the T-cell blasts with [35S]Cys and
analyzed the cell lysate by two dimensional electrophoresis under
nonreducing conditions. A spot was found in the autoradio-
graphic protein map with IPMr corresponding to those of Trx.
In the second part of the study, we incubated recombinant
human Trx in the presence or absence of GSSG or GSNO to
clarify the structural and functional properties of glutathiony-
lated Trx, then we analyzed the protein by matrix-assisted laser
desorption ionization–time-of-f light (MALDI-TOF). Finally,
we studied the effect of incubation with GSSG on the activity of
Trx coupled to NADPH as a substrate for Trx reductase (TrxR).
The results confirm that Trx can undergo glutathionylation,
which is able to regulate its enzymatic activity and function.
Materials and Methods
Materials. GSH, GSSG, GSNO, N-ethylmaleimide (NEM), and
diamide were from Sigma. TrxR was prepared from bovine liver
as described (10).
T Cell Blasts. Human peripheral blood mononuclear cells (PBMC)
were isolated by using standard FicollHypaque gradients from
buffy coats of healthy donors (kindly provided by the Blood
Center of the Hospital of Magenta, Magenta, Italy). PBMC were
cultured at 1 106 cells per ml for 3 days in RPMI medium 1640
with 10% (volvol) FCS and 2 gml phytohemagglutinin
(Sigma), then washed and cultured for 3 days with 50 unitsml
human recombinant IL-2 (Chiron).
Cell Labeling and Exposure to Diamide. Cells were resuspended at
3.3 106 cells per ml and maintained throughout the experiment
in Hanks’ balanced salt solution (HBSS) containing 50 gml
cycloheximide. After 20-min preincubation in HBSScyclohex-
imide, the cells were incubated with 8 Ciml of L-[35S]Cys
[specific activity 1,000 Cimmol (1 Ci  37 GBq); Amersham
Pharmacia]. After 30 min, the cells were treated for 5 min with
1 mM diamide (Sigma), then collected by centrifugation and
either processed for electrophoretic analysis as described below,
or the proteins were precipitated with trichloroacetic acid (TCA)
at a final concentration of 5%. After five washes with 5% TCA,
the TCA-precipitable radioactivity was counted.
Protein Electrophoresis. The cell pellet (2  107 cells per sample)
was extracted with chloroformmethanol, resuspended in 8 M
urea  0.5% carrier ampholytes, and run on immobilized pH
gradients (IPG; ref. 11) covering, with an exponential course, the
pH range 4–10 (12). IPG strips were embedded on 12% poly-
acrylamide gel slabs for the second-dimensional run in the
discontinuous buffer system of Laemmli (13). Electrophoresis
was carried out under nonreducing conditions. The slabs either
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: Trx, thioredoxin; GSH, glutathione; GSSG, glutathione disulfide; GSNO,
S-nitrosoglutathione; MALDI-TOF, matrix-assisted laser desorption ionization–time-of-
flight; TrxR, Trx reductase.
See commentary on page 9617.
†S.C. and V.B. contributed equally to this work.
¶To whom reprint requests should be addressed at: Laboratory Neuroimmunology, Mario
Negri Institute for Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy. E-mail:
ghezzi@marionegri.it.








were stained with Coomassie blue and radioactivity was analyzed
with a phosphor-imager after drying, or they were used for
Western blot analysis.
Western Blot Analysis of Trx. The slabs were blotted onto a
nitrocellulose membrane in the presence of 0.01% SDS. A goat
polyclonal antibody against human Trx (14) was used at 1:200
dilution and revealed by enhanced chemiluminescence with a
horseradish peroxidase-conjugated mouse anti-goat secondary
antibody from Pierce.
Peptide Synthesis. Cys-containing Trx fragments were synthesized
by solid-phase chemistry on an Applied Biosystems 433A syn-
thesizer using N-(9-f luorenylmethoxycarbonyl) as a protective
group for the aminic residues and N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-methylmethanaminium tet-
rafluoroborate N-oxide and N,N-diisopropylethylamine as acti-
vators of carboxylic residues. Peptides were cleaved from the
resin with trif luoroacetic acidthioanisolewaterphenol
ethanedithiol in the ratio 82.5:5:5:5:2.5 (volvol), precipitated,
and washed with diethylether.
Glutathionylation of Recombinant Trx. Recombinant human Trx
was expressed in E. coli and purified as described (15). The
numbering of amino acids is calculated without taking into
account the N-terminal methionine, which is removed in rhTrx.
Before the experiments, rhTrx was fully reduced as described
below. Briefly, 500 l of the concentrated protein (2.5 mgml)
were reacted under argon flow with a 20-fold molar excess of
DTT in 50 mM Tris1 mM EDTA, pH 7.4. The reaction was
allowed to proceed for 30 min at 37°C. To remove the excess of
DTT, samples were desalted on a NAP5-column (Amersham
Pharmacia), and the exact concentration of the fully reduced
rhTrx was established by measuring the absorbance at 280 nm
using an extinction coefficient of 1.48 mgml (16). Full reduction
of rhTrx was checked by titration of the free -SH groups, as
described below.
To induce glutathionylation, rhTrx was incubated with the
indicated concentration of GSSG for 2 h at room temperature.
When indicated, rhTrx was incubated with 5 mM GSNO under
the same experimental conditions.
Mass Spectrometric Analysis of Trx. Control or glutathionylated Trx
was analyzed by a Bruker-Reflex III MALDI-TOF mass spec-
trometer. A few l of the sample were mixed with an equal
volume of a saturated solution of sinapinic acid or -ciano-4-
hydroxycinnamic acid (Sigma) in acetonitrile0.1% trif luoroace-
tic acid 1:3 (volvol); 1 l of the mixture was deposited on the
MALDI mass spectrometry target.
Titration of Free -SH Groups with 5-5-Dithiobis-2-Nitrobenzoic Acid
(DTNB). The number of free -SH groups of rhTrx was established
spectrometrically with DTNB at 412 nm (M  13.6 M1cm1),
as described (17).
Insulin Assay for Trx Enzyme Activity. The activity of human Trx was
measured as its ability to reduce insulin disulfides in the presence
of NADPH and calf thymus thioredoxin reductase (CT-TrxR;
ref. 10). The reaction mixture containing 100 mM potassium
phosphate buffer pH 7.0, 2 mM EDTA, 0.2 mM NADPH, and
0.16 mM insulin. The samples were prepared by mixing 500 l
of the reaction mixture and different concentrations of Trx (2 or
4 M) in cuvettes. The reactions were started by the addition of
38 nM TrxR, and the absorbance of the samples were read at
340 nm against blank solution, which included all reagents
except Trx.
The activity also was tested in the endpoint assay (10) by using
a 20-min incubation to determine -SH groups formed in insulin
by breaking the reaction with 6 M guanidine-HCl, 1 mM DTNB,
and reading at 412 nm.
Tryptic Digestion of rhTrx. Fully reduced rhTrx in water (8.6 M)
was reacted with 5 mM GSSG for 2 h at room temperature as
described above. Iodoacetamide was added to the reaction
mixture to a final concentration of 2 mM to block residual Cys.
The glutathionylated rhTrx was digested with trypsin (at a
trypsin:Trx ratio of 1:10, wtwt) in a solution containing 80% of
acetonitrile and 50 mM ammonium bicarbonate (18). The
reaction was allowed to proceed for 10 min at 37°C, and the
tryptic peptides were analyzed by MALDI-TOF, as described
above. Data were compared with the theoretical molecular
weight of the rhTrx tryptic peptides, taking into consideration
the possible glutathionylated Cys.
Results
Identification of Trx Among the Glutathionylated Protein in Oxida-
tively Stressed Lymphocytes. To identify proteins undergoing
S-thiolation in human phytohemagglutinin blasts, cells were
labeled with [35S]Cys for 30 min in the presence of cyclohexi-
mide, washed, then incubated with 1 mM diamide for 5 min.
Previous studies have shown that under these experimental
conditions, diamide induces marked 35S incorporation into pro-
teins (19).
Cell extracts were analyzed by nonreducing two-dimensional
gel electrophoresis. The Coomassie blue stain and the autora-
diography of gels from diamide-treated cells are in Fig. 1 Top and
Middle. Based on molecular weight and pI, we tentatively
postulated that one of the radioactively labeled proteins, indi-
cated by an arrow in the autoradiography shown in Fig. 1, might
be Trx. To confirm the identity of this spot with Trx, we
performed Western blot analysis by using an anti-human Trx
antibody. As shown in Fig. 1 Bottom, immunoreactive Trx was
identified, corresponding to the radioactive spot.
Glutathionylation of rhTrx by GSSG. To confirm the susceptibility of
Trx to glutathionylation and to identify the modified Cys(s), we
used pure rhTrx. The protein was treated with GSSG and then
analyzed by MALDI-TOF. rhTrx had the expected molecular
weight of 11,606.2  1.9 (n  3), and incubation with 5 mM
GSSG induced the formation of a peak of 11,911.7  1.0,
compatible with the addition of one glutathione molecule (305.5
Da). A representative analysis of rhTrx and GSSG-treated rhTrx
is shown in Fig. 2. Longer incubation times (overnight) with 5
mM GSSG induced the formation of two peaks compatible with
the addition of one or two glutathione molecules (data not
shown).
The fact that the extent of glutathionylation depends on the
concentration of the oxidant also was seen in separate experi-
ments where rhTrx was treated with 100 mM GSSG for 2 h and
the free -SH groups were titrated with DTNB. Incubation of fully
reduced rhTrx with GSSG decreased the free -SH groups from
five to one.
When rhTrx was incubated with 5 mM GSNO, under the same
experimental conditions used with GSSG treatment, only one
peak was found, corresponding to the protein with one GSH
(data not shown). We did not observe a peak corresponding to
the molecular weight of an NO adduct, suggesting that under
those experimental conditions, rhTrx is not S-nitrosylated by
GSNO, unlike other proteins (20, 21).
Identification of Glutathionylation Sites of Trx. To identify the
glutathionylation site(s), we performed tryptic digestion of fully
reduced or GSSG-oxidized rhTrx, and analyzed the tryptic
fragments by mass spectrometry. However, we could not use
standard digestion protocols as they include a reduction of the
disulfide bridges in the protein, which would also cleave the
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mixed disulfide with GSH. Because preliminary experiments
have shown that tryptic digestion under nonreducing conditions
is not efficient, we used a modified protocol with digestion in
organic-aqueous solvents (18) to ensure successful digestion of
GSSG-treated rhTrx. The results are shown in Table 1. Two
peptides of molecular mass of 1,452.6 Da and 1,580.8 Da are
generated by digestion of GSSG-treated rhTrx that are not
present in the spectrum of the untreated protein (shown in Fig.
3) and are compatible with glutathionylation of Cys-72.
To understand whether the susceptibility of Cys-72 was due to
the presence of specific f lanking amino acids or to the three-
dimensional structure of the protein, we synthesized four pep-
tides homologous to the corresponding rhTrx fragments, and
that contained at least one Cys residue (Fig. 4). These four
peptides were reacted with 5 mM GSSG and analyzed by mass
spectrometry. The results, shown in Table 2, indicate that all of
the Cys-residues can be glutathionylated when they are not
involved in the three-dimensional structure of the protein. It is
of interest to note that only one glutathione molecule is attached
to the peptide 28–37 which comprises the two Cys of the active
site of Trx.
Effect of Glutathionylation on Trx Activity. To investigate the effect
of glutathionylation on the enzymatic activity of Trx, we incu-
bated Trx with 5 mM GSSG, removed GSSG by desalting on a
Sephadex G25 NAP5 column, and then evaluated disulfide
reduction with insulin as a substrate. Glutathionylation reduced
the activity of Trx to 63% of the control using an endpoint assay
of formed -SH groups in insulin by a 20-min incubation. The
attachment of a GSH residue on the -SH group of Cys-72, which
is located in the active site surface of Trx, would be expected to
abolish the activity of Trx-S2 as a substrate for TrxR. To study
this further, we used an assay where the kinetics of insulin
disulfide reduction was followed in time as the oxidation of
NADPH at 340 nm (Fig. 5). As can be seen from Fig. 5 A and
B, the initial rate of the reaction with Trx-SG was almost zero,
and the activity then was gradually regained. Thus, glutathio-
nylation operated as a reversible regulatory device of the
activity.
Discussion
This study shows that Trx can be glutathionylated under condi-
tions of oxidative stress. Glutathionylation was confirmed by
Fig. 1. Two-dimensional gel electrophoretic analysis of glutathionylated
proteins. T cell blasts (106 per sample) were labeled with 35S, then exposed to
1 mM diamide for 5 min; the proteins were separated by isoelectrofocusing
(pH range 4–10, left to right) and then by SDS10% PAGE (migration from top
to bottom). All runs were done under nonreducing conditions. Figure shows
the portion of the gel where Trx is migrating. (Top) Coomassie blue staining.
(Inset) Portion of the gel for which autoradiography and Western blot are
shown. (Middle) Autoradiography. (Bottom) Immunoblotting with anti-Trx.
Fig. 2. MALDI identification of glutathionylated Trx. HrTrx (10 pmol) was
incubated at room temperature without or with 5 mM GSSG and analyzed by
MALDI-TOF MS.
Table 1. List of tryptic fragments of glutathionylated rhTrx















rhTrx was treated with GSSG 5 mM for 2 h at room temperature and
subjected to tryptic digestion; the fragments were analyzed by MALDI-TOF.
Glutathionylated fragments are shown in italics.
*Methionine oxidized to sulfoxide (MSO).
†Fragment 1148.7  one GSH moiety (305 kDa).
‡Fragment 1276.6 and  one GSH moiety.








incubating rhTrx with GSSG at a concentration (5 mM) that can
be observed in vivo under conditions of oxidative stress or in
cellular compartments such as the endoplasmic reticulum where
the GSHGSSG ratio can be 1 (22).
The mass spectrometric analysis showed that, at a GSSG
concentration of 5 mM, only one GSH can be attached to rhTrx
at Cys-72. This higher susceptibility of Cys-72 to oxidation is
very likely caused by the fact that it is easily accessible in the
active site surface of the three-dimensional structure of Trx
(23). In fact, when we synthesized peptides reproducing partial
Trx sequences and treated them with GSSG, we found that all
Cys with the exception of one of those in the CGPC active site
were equally susceptible to glutathionylation. Thus the sus-
ceptibility of Cys-72 appears to be observed only within the
entire protein with its three-dimensional structure. Further
supporting the concept that Cys-72 is the Cys residue of rhTrx
most exposed to oxidizing agents, we noted that iodoacetamide
treatment of rhTrx under nondenaturing conditions alkylated
only Cys-72 (data not shown). Alkylation under nondenaturing
conditions has been used to determine oxidant-sensitive Cys
(also in terms of accessibility in the native structure; refs. 24
and 25). Thus, in the case of Trx, susceptibility to glutathio-
nylation is mainly due to the three-dimensional structure
rather than to the chemical-physical properties of the amino
acids in the vicinity, as has been suggested for other proteins
(26). A glutathione adduct on Cys-72 also might be favored by
the primary structure, however, as this amino acid is next to a
basic one, Lys-71, which might stabilize the adduct by inter-
acting electrostatically with the -glutamyl group of GSH (27).
Interestingly, Cys-72 is also involved in the dimerization of Trx
(23, 28), which may occur under oxidative conditions or spon-
taneous oxidation, confirming that Cys-72 can be easily oxidized.
The fact that the same Cys-72 of Trx can be involved in both the
dimerization and in the glutathionylation of Trx suggests that
glutathionylation prevents dimer formation. In fact, we found
that in the absence of GSSG, the mass spectra of rhTrx revealed
some Trx dimers, whereas in GSSG-treated rhTrx, no dimer was
detectable (data not shown).
Analysis by MALDI-TOF of rhTrx exposed to GSSG for
longer periods (overnight) showed that two GSH residues can be
attached to a single rhTrx molecule. This finding would imply
that one of the two Cys that can undergo glutathionylation is
Cys-72 and the other is either Cys-61 or Cys-68. In fact, a mixed
disulfide between glutathione and one of the Cys of the CGPC
active site (Cys-31, Cys-34) would be highly unstable (25). In
agreement with this hypothesis, we observed that even when
a synthetic peptide containing the CGPC active site was
treated with GSSG, no adduct was ever formed with two
GSH molecules.
The fact that Trx can be glutathionylated raises the question
of how this fact affects its activities. We investigated whether
glutathionylation affected its enzymatic activity. Glutathiony-
lated rhTrx lost all activity initially, but gradually, the activity was
restored with time. This was probably due to the fact that Trx
can reduce mixed disulfides (29), though not as efficiently as
glutaredoxin, and its residual activity could reactivate itself
according to the proposed scheme:
Fig. 5. Effect of glutathionylation of thioredoxin on its activity. Trx in TE
buffer was incubated with 5 mM GSSG for 2 h, GSSG was removed on a
Sephadex G25 column, and insulin disulfide reductase activity was determined
with 38 nM CT-Trx plus 2M Trx (A) or with 4M Trx (B). Activity was followed
by oxidation of NADPH in the spectrophotometer.









a 979.4 979.4 1306.5†
b (C72S) 951.4 951.5 1256.6
c (C68S) 1041.5 1041.5 1369.0†
d 1109.5 1109.5 1414.5
*From Fig. 4.
†Corresponding to the form  1 Na.
Fig. 3. Tryptic fragments obtained from the digestion of untreated or
GSSG-treated rhTrx. Only the portion of the mass spectrum comprising the
glutathionylated fragments is shown.
Fig. 4. Design of synthetic peptides spanning Cys-containing regions of
rhTrx. The four synthetic peptides (a, b, c, and d) are shown in relation to the
sequence of rhTrx. To have a single Cys for each peptide (with the exception
of the active site Cys-31 and -34) in peptide b, a Ser was substituted for Cys-72,
and in peptide c, a Ser was substituted for Cys-68.
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Trs  S2  NADPH  H3 Trx  (SH)2 NADP




Trx  S  SG
S2
P
Trx  SH  GSH active
Trx  (SH)2 Trx  S2
The finding that Trx can be regulated by glutathionylation
indicates the existence of crosstalk between the glutathione
glutaredoxin system and the Trx system through which Trx
activity can be influenced by the GSHGSSG ratio, an indicator
of the redox state of the cell. The observation that GSNO also
can induce glutathionylation of Trx with the same efficiency as
GSSG suggests that, through the formation of GSNO, NO can
influence Trx activity.
Although we demonstrate the occurrence of Trx glutathiony-
lation in living cells exposed to an exogenous oxidant in the
present work, other reports show that S-thiolathion of enzymes,
namely glyceraldehyde-3-phosphate dehydrogenase, with loss of
enzyme activity, can take place during physiologic oxidative
stress such as that induced by monocyte activation (30). There-
fore, it will be important to evaluate whether Trx is glutathio-
nylated under pathological conditions resulting in oxidative
stress.
It should be noted that although glutathionylation reduces the
enzymatic activity of Trx, it could have more subtle effects on
other activities of this protein, altering its affinity for interacting
proteins or even generating new activities. For instance, in a
protein related to Trx, sharing its insulin disulfide reducing
activity, glycosylation inhibiting factormacrophage migration
inhibitory factor, S-thiolation caused conformational changes
and generation of a growth factor like bioactivity (31). Trx has
many biological activities, whose mechanisms are largely ob-
scure: it acts extracellularly as a cytokine, chemokine, or growth
factor (32–34) and intracellularly as a regulatory protein that
influences several regulatory proteins such as NF-B (35) and
ASK1 (36), and it is efficiently secreted through a still unknown
mechanism. The relevance of the posttranslational modification
of Trx reported here warrants further investigation.
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